Dr. Helmut Sparrer was awarded a PhD at the University of Regensburg and completed his industrial and academic training with two postdoctoral positions at Roche Diagnostics (Penzberg, Germany) and the University of California, San Francisco (USA). He subsequently joined Novartis AG, Basel in 2001, where he developed innovative therapies for autoimmune and inflammatory diseases. In 2021, he co-founded Palto Therapeutics to shape the key scientific concepts of targeted delivery of RNA silencing drugs to patients. In May 2023, he co-founded Salvina Therapeutics to advance innovative concepts to break current efficacy limits in autoimmune diseases. Dr. Sparrer is contributing his expertise in biochemistry, immunology and pharmacology to Salvina Therapeutics as chief scientific officer.